WIA-SPACE-009 is the Space Radiation Protection standard, version 1.0. Its status is Active, it was published on 2025-01-26, and it is filed under Space Safety / Radiation Protection. The Radiation Protection Working Group prepared it and the WIA Standards Committee approved it. The next scheduled review is 2027-01-26. The guiding philosophy is ๅผ็ไบบ้ (Hongik Ingan), "Benefit All Humanity". In a radiation context this means the crew's long-term health, and not only mission success, is the thing being protected.
The standard follows a four-Phase architecture. Phase 1 defines the wire-format envelopes, Phase 2 exposes them over HTTPS, Phase 3 wraps them in protocol exchanges that cross trust boundaries, and Phase 4 integrates the result with the surrounding agency and standards ecosystem. This chapter is built mainly on the Phase 4 material. That material covers post-mission health monitoring, quality assurance, future development, compliance and certification, and the cross-walk to external standards. The table maps the topics of this chapter to the parts of the standard that govern them.
| Chapter topic | Where the standard addresses it |
|---|---|
| Sources, transport, environment models | Standards cross-walk (GCR, trapped radiation, SPE forecasting, geomagnetic cutoff) |
| Health effects and career risk | Post-mission monitoring; NASA HRP and lifetime surveillance integration |
| Shielding | Material QA; documented shielding analysis; future roadmap |
| Dosimetry and alerts | Equipment calibration; quality-management integration |
| Operations | Training, audits, certification process |
| Countermeasures | Medical preparedness; research priorities |
Appendix A of the standard also fixes a shared vocabulary: ARS, CME, DSB, EVA, GCR, G-CSF, HZE, ISS, ISRU, LET, LEO, OSL, REID, SAA, SPE and TLD. The sections below use these acronyms with those meanings.
Spaceflight radiation protection is not a single-document discipline. The terrestrial foundation is ICRP 103, the 2007 Recommendations of the International Commission on Radiological Protection. Its justification, optimisation and dose-limitation principles are the common root of all later guidance. NCRP then adapts those principles to spaceflight in a family of reports. NCRP 132 gives guidance for activities in low-Earth orbit. NCRP 142 describes an operational radiation safety programme for astronauts in LEO. NCRP 153 lists the information needed for recommendations beyond LEO. NCRP 167 examines how individual genetic susceptibility and previous radiation exposure alter an astronaut's risk. NASA-STD-3001 Volume 1 (Crew Health) and Volume 2 (Human Factors, Habitability, and Environmental Health) place these ideas inside the agency's medical and habitability requirements.
The standard's cross-walk assigns one authoritative reference to each concern, so implementers do not have to reconcile competing documents:
| Concern | Reference |
|---|---|
| Radiation-protection principles | ICRP 103 |
| Space-flight radiation protection | NCRP 132, 142, 153, 167 |
| Operational dosimetry | NCRP 142 and NCRP 156 |
| GCR transport modelling | HZETRN 2015, GEANT4, FLUKA, PHITS |
| Trapped-radiation modelling | AE-9 / AP-9 / IRENE |
| SPE forecasting | NOAA SWPC and ESA SEPEM |
| Quality management for dosimetry | ISO/IEC 17025 and ANSI N13.11 |
| Lifetime astronaut health | NASA Lifetime Surveillance of Astronaut Health |
On the agency side, the NASA Human Research Program (HRP) supplies an integrated risk model that feeds the operator's lifetime career-dose envelope. The Space Radiation Analysis Group (SRAG) at JSC receives in-flight dose data. The standard's job is to make these independently maintained bodies of guidance fit together in one mission plan.
Three source classes dominate crew exposure. Galactic cosmic rays (GCR) are a continuous, penetrating background that includes high-charge, high-energy heavy ions, the HZE component. Solar particle events (SPE), often associated with coronal mass ejections (CME), are sporadic and can deliver a large dose in a short time. Trapped radiation in the Earth's belts matters mainly in LEO. The South Atlantic Anomaly (SAA), where the inner belt dips close to the planet, produces a visible rise in dose rate on every ISS orbit that crosses it.
The quantity that links these particles to biology is linear energy transfer (LET), the energy a particle deposits per unit path length. Heavy ions have high LET and cause dense, clustered damage. This is why absorbed dose alone under-describes the hazard, and why the standard works with dose-equivalent style risk measures rather than raw absorbed dose.
Each source class has its own model family in the cross-walk:
The standard also looks beyond LEO. Its reference scenario for a Mars-class mission accumulates GCR exposure of more than 0.5 Sv. That figure puts deep-space missions in a different regime from ISS operations, where the geomagnetic field and short mission duration keep the problem tractable.
The standard distinguishes acute and long-term consequences. Acute radiation syndrome (ARS) is the deterministic response to a very large dose in a short time, which is the credible outcome of an unshielded SPE. Long-term concerns are stochastic and degenerative. They include cancer, cataracts, cardiovascular effects and effects on the central nervous system (CNS) and cognition. At the cellular level, the double-strand break (DSB) is the key lesion, and the clustered DSBs caused by HZE particles are among the hardest for cells to repair correctly.
Risk is expressed as the Risk of Exposure-Induced Death (REID). The HRP integrated risk model feeds the operator's lifetime career-dose envelope, so a single mission is judged against what the astronaut has already received. NCRP 167 adds that individual genetic susceptibility and previous exposure modify the result. The standard lists personalised limits and individual radiosensitivity as a research priority, with biomarkers such as the gamma-H2AX foci assay, the chromosomal aberration assay (per the IAEA Cytogenetic Manual) and single-cell sequencing of damage-response signatures.
Post-mission surveillance closes the loop between prediction and observation. Within 7 days of landing, the standard requires the following:
| Item | Content |
|---|---|
| Physical examination | Complete examination |
| Blood tests | Complete blood count and biomarkers |
| Cytogenetics | Chromosome aberration analysis |
| Neurocognitive | Cognitive function testing |
| Eyes | Ophthalmological exam |
| Dose verification | All dosimeter read-outs, final dose assessment, career dose update |
Long-term follow-up is annual: a comprehensive health assessment, cancer screening at enhanced frequency, cardiovascular evaluation, cognitive testing and cataract screening. The results go into a lifetime database of individual health records, exposure history, correlation analyses and epidemiological studies. The NASA Lifetime Surveillance of Astronaut Health programme runs the physicals and the cancer, cataract and cardiovascular screening under the operator's lifetime-surveillance protocol.
Shielding in space differs from shielding for gamma sources on Earth. Heavy ions fragment when they strike dense, high-Z material, and the fragments and secondary neutrons can add to the dose behind the wall. Hydrogen-rich materials such as polyethylene and water are therefore favoured per unit mass, because hydrogen fragments heavy ions with less secondary production. For an SPE, which is dominated by protons, added passive mass in a designated shelter region is effective, and that is the basis of storm-shelter operations.
The standard treats shielding as an engineering claim that has to be evidenced. A mission must provide a documented shielding analysis, which in practice means transport calculations using the codes listed in section 7.3. Material quality is checked by composition verification, density measurements and quality-control sampling. These checks matter because the transport model assumes a particular areal density and composition, and a deviation in the delivered hardware invalidates the calculation behind it.
Beyond conventional structures, the standard's roadmap names:
The active-shielding research it cites includes magnetic deflection as studied under NIAC, electrostatic deflection and a plasma magnetic-bottle concept. These remain research topics. The standard does not treat any of them as a substitute for a passive design that meets its compliance requirements today.
The standard names the dosimeter families used in practice: thermoluminescent dosimeters (TLD), optically stimulated luminescence (OSL) dosimeters, and tissue-equivalent proportional counters and silicon detectors (TEPC / silicon). Passive TLD and OSL elements integrate dose over a period and are read out afterwards. Active instruments give time-resolved data, which is what an alert needs. The cross-walk ties each to a reference: IAEA-TECDOC-1126 and ISO/ASTM 51539 (adapted for spaceflight) for TLD; NIST traceability and ISO/IEC 17025 for OSL; and NASA RAM with AAPM TG-43 (adapted) for TEPC and silicon detectors.
Calibration is where measurement quality is decided. The standard requires:
The energy-response requirement exists because spaceflight mixes particle types and energies that a single terrestrial check source cannot represent. The calibration laboratory operates under ISO/IEC 17025, the flight radiation-protection programme under ISO 9001, and personnel dosimetry performance follows ANSI N13.11. An independent audit runs annually and includes international intercomparisons: the BIPM key comparison, the EURADOS WG-9 spaceflight intercomparison and NIST personnel-dosimetry proficiency testing. An out-of-tolerance finding triggers corrective and preventive action under ISO 19011, with documented correction and verification that it worked.
On the data side, SRAG ingests in-flight dose data and publishes per-crew dose summaries within 72 hours of mission end. Near-term plans include wearable real-time dosimeters and improved SPE prediction models. This improves alerting, because an SPE warning is only useful if the forecast and the crew's measured dose rate reach the same decision point.
Software that carries these records follows the same layered contract as the rest of the family. Hosts log each envelope with a timestamp, host and tenant identifiers, envelope class and identifier, outcome and a trace identifier propagated through the W3C traceparent header and returned as X-WIA-Trace-Id. SIEM consumers tag these records with wia.standard.slug and wia.standard.phase. A host may publish optional capabilities at the well-known path below, and clients treat anything not listed as absent. Within the 1.x line, existing envelopes and endpoints are never removed, and a reference container with mock data lets integrators test against the conformance suite before connecting real backends.
GET /.well-known/wia-space-radiation-capabilitiesProcedures are verified as carefully as hardware. Every crew member receives radiation safety training, with an annual refresher. Simulation exercises cover SPE response and ARS treatment, because those are the events where a delay of minutes changes the outcome. Audits occur at three points: before the mission to verify equipment and procedures, during the mission as a periodic ground review, and afterwards as a lessons-learned analysis.
A mission demonstrates compliance with a package of evidence: a pre-mission radiation protection plan, a documented shielding analysis, dosimetry system verification, crew training records and a medical preparedness assessment. Certification is a six-step sequence:
1. Submit mission radiation profile
2. Review by WIA Radiation Safety Board
3. Pre-launch inspection
4. In-mission monitoring
5. Post-mission evaluation
6. Certification issuance or recommendationsThe standard sits alongside agency processes and does not replace them. Its compliance envelope refers to NASA NPR 7120.5 (programme and project requirements) and NPR 8715.7 (payload safety for expendable launch vehicles). It also refers to NASA-STD-3001 Volumes 1 and 2, ESA's ECSS-Q-ST-30 (product assurance) and ECSS-E-ST-10-04 (space environment), JAXA JX-ESPC-100133 for manned space activities, CSA RS-1100 on human research ethics and Roscosmos GOST R 25645.115. Operator certification includes review and sign-off by an independent technical authority (NESC at NASA, with equivalents at partner agencies) as part of flight-readiness review.
International missions require shared dose data. The operator's cross-comparison with ESA EAC, JAXA AAPM, CSA and Roscosmos IBMP follows a bilateral memorandum-of-understanding arrangement for dose-data sharing. Because these records are crew health data, the cross-walk names the privacy regimes that apply: HIPAA, the NASA Privacy Act, GDPR and LGPD. Envelopes that carry personal data must respect data-minimisation, purpose-limitation and storage-limitation principles. If an envelope crosses a jurisdictional border, the transfer mechanism (for example SCC for the EU) is referenced in the audit record.
Countermeasures in the standard are split into what must be ready now and what is still research. For now, the requirement is medical preparedness for ARS, assessed as part of compliance and rehearsed in simulation exercises. G-CSF (granulocyte colony-stimulating factor) appears in the acronym list as an established agent used against the loss of white blood cells that characterises ARS. The standard does not give dosing, which is a clinical matter for the flight surgeon and the medical protocols of the operating agency.
Several countermeasures remain in research and are labelled that way. NASA NSCOR work covers antioxidant cocktails, and ESA studies explore hibernation-induced radioprotection, which the standard marks as research only. The roadmap places personalised radioprotective pharmaceuticals in the 2030-2040 window and puts gene therapy for radiation resistance and regenerative medicine for radiation damage after 2040. Individual radiosensitivity biomarkers are the enabling step, because a personalised countermeasure needs a measurable indicator of who is more vulnerable.
Medical readiness also depends on records. The post-flight examination, the annual follow-up and the lifetime database described in section 7.4 are how the effectiveness of countermeasures will eventually be judged. Their personal data is subject to the privacy rules in section 7.7. Subject-rights functions (access, rectification, erasure, portability, restriction and objection) are provided by WIA-OMNI-API and are not rebuilt in this standard.
The roadmap in the standard has three horizons, summarised here:
| Horizon | Shielding and monitoring | Biomedical |
|---|---|---|
| Near term (2025-2030) | Nanotechnology passive materials; wearable real-time dosimeters; better SPE prediction | Biomarker development |
| Mid term (2030-2040) | Active electromagnetic shielding demonstrations; ISRU shielding (regolith, Martian soil) | Personalised radioprotective pharmaceuticals |
| Long term (2040+) | Compact active shielding for deep-space vehicles | Gene therapy for radiation resistance; regenerative medicine |
Five research priorities are listed, in this order:
Each priority addresses a gap in the current risk model. The model is largely calibrated on terrestrial and acute exposures, while a Mars-class crew will receive chronic, low-dose-rate, heavy-ion-rich exposure while also living under other stresses. The cross-agency view is carried by the ISECG Global Exploration Roadmap, section 4.5, which the standard uses to align its roadmap with partner agencies.
This chapter followed WIA-SPACE-009 from the radiation environment to the astronaut's health records after landing. GCR, SPE and trapped radiation are characterised by LET and modelled with transport and environment codes. Biological risk is tracked as REID against a lifetime career-dose envelope. Passive shielding is a documented, material-verified claim, while active concepts remain research. Dosimeters are calibrated annually against NIST-traceable sources under ISO/IEC 17025 and audited through international intercomparisons. Operational protocols, from annual training to the six-step certification, tie these elements together. Crew health data stays protected as it moves between agencies.
The key design choice in Phase 4 is that the standard does not compete with ICRP, NCRP, NASA-STD-3001 or the ECSS documents. It places each in a defined role, so a mission that satisfies the cross-walk can show where every dose number, calibration record and medical finding came from. Surveillance after the mission also feeds back into what the next mission's plan assumes. That feedback loop, from measured exposure and outcomes back to planning limits, is the thread the next chapter picks up as the guide moves from the radiation-protection domain to the broader implementation concerns that follow it.